Compare stocks

KYMR vs PHAR

Kymera Therapeutics, Inc. Common Stock and Pharming Group N.V. ADS, each representing 10 ordinary shares

Compare the businesses

Kymera Therapeutics, Inc. Common Stock

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Open KYMR dashboard ↗

Pharming Group N.V. ADS, each representing 10 ordinary shares

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Open PHAR dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗